Stereotactic body radiotherapy for liver cancer shows long-term safety

In a follow-up to a previous study on the safety and efficacy of stereotactic body radiotherapy for patients with small hepato-cellular carcinomas, researchers found that incidence of grade 3 or higher adverse events did not increase after longer follow-up times.